Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rethinking bioactivity of FLT3 inhibitors

Published byPaule Truchon Modified over 5 years ago

Similar presentations

Presentation on theme: "Rethinking bioactivity of FLT3 inhibitors"— Presentation transcript:

1 Rethinking bioactivity of FLT3 inhibitors
by Thomas Fischer Blood Volume 117(12): March 24, 2011 ©2011 by American Society of Hematology

2 FL indicates FLT3 ligand; E, extracellular domain of FLT3; TM, transmembrane domain; JM, juxtamembrane domain; TKD1, tyrosine kinase domain 1; TKD2, tyrosine kinase domain 2; TKI, tyrosine kinase inhibitor; AGP, alpha-1 acid glycoprotein; and FLT3-ITD, FLT3... FL indicates FLT3 ligand; E, extracellular domain of FLT3; TM, transmembrane domain; JM, juxtamembrane domain; TKD1, tyrosine kinase domain 1; TKD2, tyrosine kinase domain 2; TKI, tyrosine kinase inhibitor; AGP, alpha-1 acid glycoprotein; and FLT3-ITD, FLT3 receptor with internal tandem duplication mutation. Thomas Fischer Blood 2011;117: ©2011 by American Society of Hematology

Download ppt "Rethinking bioactivity of FLT3 inhibitors"

Similar presentations

Acute Leukemia and the FLT3 Receptor By: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.

Acute Leukemia and the FLT3 Receptor By: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.
Acute Leukemia and the FLT3 Receptor B y: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.

Acute Leukemia and the FLT3 Receptor B y: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.
Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87. Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87.

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):
Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia Michael R. Grunwald, Li-Hui.

Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia Michael R. Grunwald, Li-Hui.
Samsung Genome Institute Samsung Medical Center

Samsung Genome Institute Samsung Medical Center
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.

RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
CD146: a new partner for VEGFR2

CD146: a new partner for VEGFR2
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
by Timothy P. Hughes, and David M. Ross

by Timothy P. Hughes, and David M. Ross
by James O. Armitage, and Dan L. Longo

by James O. Armitage, and Dan L. Longo
VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo,
Another Notch on the belt

Another Notch on the belt
Ambiguous Origin: Two Sides of an Ephrin Receptor Tyrosine Kinase

Ambiguous Origin: Two Sides of an Ephrin Receptor Tyrosine Kinase
Thanks for the complement (inhibitor)‏

Thanks for the complement (inhibitor)‏
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
BRAF inhibitor: targeted therapy in hairy cell leukemia

BRAF inhibitor: targeted therapy in hairy cell leukemia
Activation of the Erythropoietin Receptor Is Not Required for Internalization of Bound Erythropoietin by Diana L. Beckman, Lilie L. Lin, Mary E. Quinones,

Activation of the Erythropoietin Receptor Is Not Required for Internalization of Bound Erythropoietin by Diana L. Beckman, Lilie L. Lin, Mary E. Quinones,

Similar presentations

Ads by Google